Claudio Verusio

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 404 citations · Full text

Breast Oncology, Overall Survival, Medicine +7

Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

Ugo De Giorgi, Giuseppe Procopio, Diana Giannarelli et al. · Clinical Cancer Research · 2019 · 233 citations · Full text

Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial

Daniela Cardinale, Fabio Ciceri, Roberto Latini et al. · European Journal of Cancer · 2018 · 224 citations

International Cardiooncology Society-one, Preventive Medicine, Cardiovascular Disease +9

Crizotinib in <i>MET</i> -Deregulated or <i>ROS1</i> -Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial

Lorenza Landi, Rita Chiari, Marcello Tiseo et al. · Clinical Cancer Research · 2019 · 183 citations · Full text

ROS1-rearranged Non–small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS)

Rita Chiari, Biagio Ricciuti, Lorenza Landi et al. · Clinical Lung Cancer · 2019 · 97 citations

Thrombosis, Venous Thrombosis, Phase Ii +11